MarketVue® Report
Diabetic Retinopathy (DR) (U.S.), 2021

Syndicated market assessment report driven by primary market research

REPORT STORE

Diabetic Retinopathy (DR) (U.S.), June 2021

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Diabetic Retinopathy market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Diabetic Retinopathy report is supported by 3 qualitative interviews with key opinion leaders, a quantitative survey with 19 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Regeneron Pharmaceuticals
  • Novartis
  • Hoffmann-La Roche
  • Adverum Biotechnologies
  • Regenexbio
  • Oxurion
  • Graybug Vision
  • Kubota Vision
  • Opthea
 
Key drugs mentioned:
  • Aflibercept (Eylea)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin)
  • Faricimab (Vabysmo)
  • Ranibizumab port delivery system (Susvimo)
  • Brolucizumab (Beovu)
  • RGX-314
  • ADVM-022
  • THR-149
  • GB-102
  • Emixustat
  • OPT-302
  • THR-687
1. DISEASE OVERVIEW
Blood vessel impairment underlies vision impairment in diabetic retinopathy
Hallmarks of diabetic retinopathy
Figure 1.1. Stages of diabetic retinopathy
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Diagnosed prevalent cases of diabetic retinopathy by region
Table 2.1. Diagnosed prevalent and drug-treated diabetic retinopathy patients in the US and EU5
Figure 2.2. Segmentation of total prevalent cases of diabetic retinopathy by severity
3. CURRENT TREATMENT
Treatment goals
Figure 3.1. Treatment goals for diabetic retinopathy
Standard of care
Figure 3.2. Patient share of anti-VEGF treatment
Table 3.1. Current anti-VEGF usage by retinal specialists
Treating physicians
Referring physicians
Figure 3.3. Diagnosis and treatment flow for diabetic retinopathy
Must-know treatment dynamics for diabetic retinopathy
Barriers to patient care
Figure 3.4. Percent of retina specialists rating factor as “impactful”
Figure 3.5. Potential timeline of diabetic retinopathy market evolution
Is earlier treatment with current therapies on the horizon? Not so fast.
Figure 3.6. Retina specialist experimentation with anti-VEGF for NPDR
4. UNMET NEED
Treatment-related unmet needs
Figure 4.1. Top unmet needs in diabetic retinopathy
Figure 4.2. Percentage of retina specialists ranking unmet need in their top two
Unmet need by type of diabetic retinopathy
Figure 4.3. Percentage of retina specialists citing extremely high unmet need by disease type
Early prevention and reversal of disease progression
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Number of emerging therapies addressing unmet needs in diabetic retinopathy
Gene therapy has caught the eye of retinal specialists
Figure 5.2. Percent of retina specialists rating target/approach as “promising”
Table 5.1. Emerging therapies in clinical development for diabetic retinopathy
Retina specialists’ pipeline knowledge
Figure 5.3. Percent of retina specialists familiar with emerging therapy
6. VALUE & ACCESS
Overview
Table 6.1. Annual cost and sales of anti-VEGF therapies
CMS is the predominant payer for diabetic retinopathy patients
Figure 6.1. Payer mix for diabetic retinopathy
Figure 6.2. Phase III biosimilars on the horizon for Eylea and Lucentis
7. METHODOLOGY
Primary market research methodology
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us